Stereotactic radiation for central lung tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a precise, high-dose radiation treatment aimed at central lung tumors. It may help people who cannot have lung surgery and whose tumors can be safely targeted near sensitive organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent
- You should have an expected survival of more than 6 months
- You should be well enough for daily activities (performance status 0 to 2)
- Your lung cancer must be either early primary non-small cell lung cancer, or one limited lung spread spot (oligometastasis)
- Your tumor must be central, but the treatment plan must fit safety limits for nearby organs and be decided by a specialist team
- You must be able to follow study visits and procedures, including a 4D-CT scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether giving a higher dose of radiation to the tumour, while still keeping the dose to nearby organs safe, can improve control of the cancer. It's for people with early-stage lung cancer (or a single spot of cancer in the lung from another cancer) who are not suitable for or refuse surgery. The treatment specifically targets tumours that are near the chest wall, where a standard approach might not be safe, and uses a special planning scan to guide the dose.
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
This trial tests whether adding focused, high-dose radiation (SABR) to standard drug therapy can better control cancer that has spread to a few spots in the body. It is for people starting or resuming cancer medicines for newly found or growing metastases.
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.
Hear when a new NSCLC/Oligometastatic Cancer (Single Lung Lesion) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.